predict incident AKI and in some cases, earlier than when changes in creatinine or eGFR may occur. [4] [5] [6] In recent studies, machine learning was employed to develop models that predicted AKI in hospitalized patients with excellent accuracy; 7, 8 and similarly, genomic and proteomic characterization of AKI has been undertaken with varying results. [9] [10] [11] To the best of our knowledge, machine learning for prediction of AKI in patients undergoing coronary angiography has not yet been studied. As such, we hypothesized that a proteomics-based and artificial intelligence-driven biomarker approach together with clinical risk factors would predict procedural AKI risk in patients enrolled in the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) undergoing coronary angiographic procedures with or without interventions for various acute and non-acute indications.
| METHODS
All study procedures were approved by the Partners Healthcare Institutional Review Board and carried out in accordance with the Declaration of Helsinki.
The design of the CASABLANCA (NCT NCT00842868) study has been detailed previously. 12 Briefly, 1251 patients undergoing coro- Median follow-up was 4 years, with a maximum follow-up of 6 years. Follow-up was complete for all patients. Processes for identification and adjudication of clinical endpoints were as previously described 12 and included review of medical records, as well as phone follow-up with patients and/or managing physicians and was performed by physicians blinded to biomarker concentrations. The Social Security Death Index and/or postings of death announcements were used to confirm vital status. A detailed definition of endpoints for CASABLANCA was previously published. 12 Specific to this analysis, procedural AKI was defined as an abrupt reduction in kidney function with an absolute increase in serum creatinine of more than or equal to 0.3 mg/dL, a percentage increase in serum creatinine of ≥50%, or a reduction in urine output (documented oliguria of <0.5 mL/kg per hour for >6 hours), within 7 days after contrast exposure.
Baseline characteristics between those who developed procedural AKI and those who did not were compared. A complete case analysis was performed; blood urea nitrogen, or creatinine values were missing with some patients (n = 167), so these patients were removed from the analysis. One other patient was removed from the analysis for having an insufficient quantity of sample, leaving 889 samples available for analysis. For any biomarker result that was below the limit of detection, we utilized a standard approach of imputing concentrations 50% below the limit of detection.
To facilitate the machine learning analysis, the concentrations for all proteins underwent the following transformations: (a) they were log-transformed to achieve a normal distribution, (b) outliers were clipped at the value of three times the median absolute deviation, and mance using the MCCV process described above, and we also determined its in-sample performance using a final prognostic model developed on all of the available data with LASSO with logistic regression. A cutoff was determined using the optimal Youdens index.
In all statistical analyses, a two-tailed P-value of <0.05 was considered statistically significant. All analyses were performed using the R statistical computing platform, version 3.4.4.
| RESULTS
Forty-three (4.8%) patients developed procedural AKI. Those who developed procedural AKI were older (70 vs 67 years of age, P = 0.04) and more likely to have prevalent diabetes mellitus (41.9% vs 23.5%, P = 0.01) or CKD (20.9% vs 10.4%, P = 0.04) ( Table 1) . Those who developed procedural AKI also had lower left ventricular ejection fraction at baseline (50.0% vs 56.6%, P = 0.04) and a higher percentage of them were prescribed an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) compared to those who did not develop AKI (72.1% vs 53.6%, respectively, P = 0.02) ( Table 1) .
As expected, those who developed procedural AKI had higher Those who developed procedural AKI had numerically lower concentrations of CD5 antigen-like (3600 vs 3755 pg/mL) compared to those with did not develop procedural AKI (Table 1) .
Following our machine learning-driven approach to panel development, six predictors were present in the final model: four (history of diabetes, BUN/creatinine ratio, CRP, and osteopontin) had a positive association with AKI risk; while two (CD5 antigen-like and Factor VII)
had a negative association with AKI risk. Using the model-building procedure described above for subsets of variables, the addition of each biomarker provided a statistically significant improvement in the AUC and the likelihood ratio, while decreasing the AIC and the BIC ( Table 2 ).
The final model had a cross-validated area under the receiver operating characteristic curve (AUC) of 0.79 for predicting procedural AKI, and an in-sample AUC of 0.82 (P < 0.001). The optimal score cutoff had 77% sensitivity, 75% specificity, and a negative predictive value of 98% for procedural AKI (Figure 1 ). An elevated score was predictive of procedural AKI in all subjects (odds ratio = 9.87; P < 0.001).
In addition, we tested our model in several subgroups and found that in women (n = 358) the AUC = 0.76; in those whose age ≥ 75 years The rationale for our study is based on the fact that AKI following coronary angiographic procedures is associated with significant morbidity and mortality that has potential to alter patient management if predicted early. enzyme, and need for cardiac surgery after contrast exposure were associated with increased risk of procedural AKI. 15 Mehran et al developed a simple risk score that included pre-and periprocedural risk factors including hypotension, intra-aortic balloon pump, HF, CKD, diabetes, age > 75 years, anemia, and volume of contrast with good discriminative power (c-statistic 0.67). 4 In another AKI risk prediction model developed by Brown et al, pre-procedural serum creatinine, HF, and diabetes accounted for >75% of the predictive model. 16, 17 While BUN and serum creatinine are most often used to predict procedural AKI, they are not very sensitive or specific for the diagnosis of AKI because they are affected by many renal and non-renal factors that are independent of kidney injury or kidney function. 18 As such, several biomarkers and biomarker panels with and without clinical risk factors have been examined to more accurately predict AKI.
Our risk prediction model included the BUN/creatinine ratio in addition to clinical and biomarker risk factors to better predict procedural AKI. Given the proximity of collection of pre-and post-procedure samples and the slower rise in creatinine, than BUN, it is understandable why the BUN and ratio of BUN/creatinine was predictive of renal dysfunction than creatinine alone.
Inflammation may play an important role in presence and severity of AKI. CRP is an acute-phase protein of hepatic origin that is a marker of inflammation synthesized in response to factors released by macrophages and adipocytes. 19 CRP has been associated with cardiovascular risk 20 and has also been associated with renal dysfunction. 21 Tang et al demonstrated that elevated serum CRP concentrations were associated with increased serum creatinine and urea concentrations (P < 0.01) in patients with AKI; CRP concentrations subsequently AKI, acute kidney injury; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CKD-EPI, chronic kidney disease-epidemiology; CVA/TIA, cerebrovascular accident/transient ischemic attack, eGFR, estimated glomerular filtration rate.
fell after recovery from AKI. 22 In older patients with AKI, CRP was an independent risk factor for mortality. 23 CRP has also been studied for its ability to predict risk for AKI. In a study of 1656 patients undergoing coronary artery bypass grafting, pre-operative CRP concentrations predicted post-operative AKI and mortality; the addition of CRP to an existing risk model improved net reclassification and discrimination. 24 That we found concentrations of CRP as a predictor of procedural AKI is consistent with this body of evidence.
Osteopontin is an extracellular matrix protein and proinflammatory cytokine thought to facilitate the recruitment of monocytes/macrophages and to mediate cytokine secretion in leukocytes. It plays a role in many physiological and pathological processes, including biomineralization, tissue remodeling, and inflammation. 25 It is found mainly in the loop of Henle and distal nephrons in normal kidneys and can be upregulated in all tubular and glomerular segments following kidney damage, and may also have a role in renal repair. 26 In the last several years, the role of osteopontin in the pathogenesis of diabetic nephropathy has been explored. 25 Osteopontin has been reported to be highly expressed in the tubular epithelium of the renal cortex and in glomeruli in rat and mouse models of diabetic nephropathy 27 and in humans, plasma osteopontin concentrations are independently associated with the presence and severity of diabetic nephropathy. 28 In a study of critically ill patients with AKI requiring renal replacement therapy, concentrations of osteopontin were significantly higher than in critically ill patients without AKI. In addition, osteopontin concentrations were found to be a strong predictor of mortality with an AUC of 0.82 (95% confidence interval [CI]: 0.74-0.89; P < 0.0001), sensitivity of 100%,and specificity of 61% for a cutoff value of 577 ng/mL. 
| CONCLUSIONS
In a typical at-risk population undergoing coronary angiography for various acute and non-acute indications, we describe a clinical and proteomics-supported biomarker model with high accuracy for predicting procedural AKI in patients undergoing coronary angiography.
The ability to predict AKI may allow for earlier interventions in at-risk patients to reduce future AKI risk. We plan to test our risk prediction model in an external validation cohort in the future.
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